Neurocrine Biosciences (NBIX) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Neurocrine Biosciences has initiated a Phase 3 study titled ‘A Phase 3, Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Assess the Efficacy of NBI-1117568 in Preventing Relapse of the Symptoms of Schizophrenia and to Assess the Safety and Tolerability of NBI-1117568 in Adults With Schizophrenia.’ The study aims to evaluate the effectiveness of NBI-1117568 in delaying relapse in adults with schizophrenia who have shown a stable response to the drug during an open-label treatment phase.
The intervention being tested is NBI-1117568, an oral capsule designed to prevent relapse in schizophrenia patients. It will be compared to a placebo to assess its efficacy and safety.
This interventional study follows a randomized, parallel assignment model with quadruple masking, involving participants, care providers, investigators, and outcomes assessors. The primary purpose of the study is treatment-focused.
The study is set to begin on November 11, 2025, with the last update submitted on the same date. The primary completion and estimated completion dates are yet to be announced, marking the study’s initial phase.
The initiation of this study could influence Neurocrine Biosciences’ stock performance positively, given the potential of NBI-1117568 to address a significant need in schizophrenia treatment. Investors may view this development favorably, especially in comparison to competitors in the psychiatric treatment market.
The study is currently not yet recruiting, with further updates available on the ClinicalTrials portal.
To learn more about NBIX’s potential, visit the Neurocrine Biosciences drug pipeline page.